GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK announced a significant board-level change at one of its Non-Executive Directors' external commitments. Wendy Becker, who serves as GSK's Non-Executive Director and Chair of the Remuneration Committee, has been appointed as Chair of the Board of Sony Group Corporation, effective June 24, 2025. This represents a promotion from her previous position as Vice Chair of Sony's Board.
This disclosure, filed as a Form 6-K (foreign issuer report), reflects GSK's commitment to transparency regarding its directors' external appointments and potential commitments. The appointment was officially documented by Victoria Whyte, GSK's Company Secretary.
- Filing Date: June 28, 2025
- Effective Date of Appointment: June 24, 2025
- Key Personnel: Wendy Becker (Non-Executive Director)
- New Role: Chair of Sony Group Corporation Board
- Previous Role at Sony: Vice Chair of the Board
GSK has reported a significant share buyback transaction on June 23, 2025. The company purchased 483,823 ordinary shares through Merrill Lynch International at prices ranging from 1,398.00p to 1,414.50p per share, with a volume-weighted average price of 1,403.43p.
Key transaction details:
- All trades were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 223,761,425 shares in treasury
- Total voting rights now stand at 4,091,584,047
- Treasury shares represent 5.47% of voting rights
This purchase is part of GSK's existing buyback program announced on June 4, 2025. Since the program's inception, the company has purchased 5,627,042 ordinary shares, demonstrating significant progress in their capital return strategy.
GSK announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application for linerixibat, a targeted inhibitor of the ileal bile acid transporter (IBAT), for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Key highlights:
- The application is based on positive results from the GLISTEN phase III trial, which met both primary and secondary endpoints
- Linerixibat demonstrated rapid, significant, and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo
- The drug addresses an unmet medical need, as up to 90% of PBC patients experience pruritus, with current first-line treatments not reducing its severity
- The trial involved 238 PBC patients across 19 countries, marking it as the first truly global PBC study
This EMA acceptance follows FDA acceptance earlier in the month. Linerixibat has received orphan drug designation from both FDA and EMA, and is currently under review in the US and UK markets.
GSK announces a significant regulatory milestone as Japan's Ministry of Health, Labour and Welfare (MHLW) accepts their application to expand the use of Arexvy, their RSV vaccine, to adults aged 18-49 at increased risk of severe RSV disease.
Key developments:
- If approved, Arexvy would be the first RSV vaccine in Japan for this age group
- Application supported by positive Phase IIIb trial (NCT06389487) data showing non-inferior immune response in at-risk adults aged 18-49 compared to those 60+
- Currently approved in Japan for adults 60+ and at-risk adults 50+
- Trial involved 1,458 participants across 52 locations in 6 countries
RSV affects an estimated 64 million people globally annually and can lead to severe complications, particularly in at-risk populations. GSK is pursuing similar regulatory expansions in the US and Europe, positioning Arexvy as a leading preventive solution for RSV disease across multiple age groups.
GSK plc submitted a Form 6-K detailing routine activity under its existing share-buyback programme. Acting through Merrill Lynch International, the company repurchased 473,254 ordinary shares on 19 June 2025 at prices ranging from 1,424.00p to 1,441.50p, producing a volume-weighted average price of 1,434.72p.
Since the mandate began on 4 June 2025, 4,664,836 shares have been acquired. The latest transaction lifts treasury holdings to 222,799,219 shares, equivalent to 5.44 % of total voting rights. Shares outstanding (excluding treasury) now stand at 4,092,502,370, which is also the updated denominator for disclosure threshold calculations under the FCA’s Disclosure Guidance & Transparency Rules.
The filing includes a granular trade log for London Stock Exchange executions; no purchases occurred on CBOE venues. All shares will be held in treasury and may be used for future capital management purposes such as employee share plans or cancellation.
GSK plc filed a Form 6-K detailing daily activity under its ongoing share repurchase programme. On 18 June 2025, the company bought 468,255 ordinary shares (31 ⅔ p nominal value) through its broker Merrill Lynch International. Purchase prices ranged from 1,444.00 p to 1,469.50 p with a volume-weighted average of 1,454.83 p per share.
The transaction forms part of the non-discretionary buyback mandate announced on 4 June 2025. Cumulatively since that date, 4,191,582 shares have been repurchased.
Following the latest purchase, GSK holds 222,325,965 shares in treasury, representing 5.43 % of voting rights. Shares outstanding excluding treasury now total 4,092,975,624; this figure is the denominator shareholders should use for FCA DTR notifications.
No financial performance metrics or strategic changes were disclosed; the filing is limited to share buyback execution details.